Glaukos (NYSE:GKOS) Given Buy Rating at BTIG Research

Glaukos (NYSE:GKOS)‘s stock had its “buy” rating restated by investment analysts at BTIG Research in a research note issued to investors on Friday,Benzinga reports. They currently have a $116.00 target price on the medical instruments supplier’s stock. BTIG Research’s target price would indicate a potential upside of 2.84% from the stock’s current price.

A number of other analysts have also weighed in on GKOS. The Goldman Sachs Group started coverage on shares of Glaukos in a research report on Wednesday, October 1st. They set a “buy” rating and a $103.00 price objective for the company. Citigroup upped their price target on Glaukos from $113.00 to $125.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Truist Financial upped their price objective on Glaukos from $120.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Stifel Nicolaus set a $115.00 target price on Glaukos in a research report on Monday, October 27th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $114.92.

Glaukos Price Performance

Shares of GKOS opened at $112.80 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47. The company’s fifty day moving average price is $100.65 and its 200-day moving average price is $94.69. The firm has a market capitalization of $6.48 billion, a PE ratio of -73.25 and a beta of 0.69. Glaukos has a 1-year low of $73.16 and a 1-year high of $163.71.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.11. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.The company had revenue of $133.54 million during the quarter, compared to analysts’ expectations of $122.55 million. During the same period last year, the business earned ($0.28) earnings per share. Glaukos’s quarterly revenue was up 38.1% on a year-over-year basis. On average, equities research analysts predict that Glaukos will post -1.08 EPS for the current year.

Insider Activity at Glaukos

In other Glaukos news, Director Gilbert H. Kliman sold 5,000 shares of the business’s stock in a transaction on Tuesday, December 9th. The shares were sold at an average price of $107.27, for a total transaction of $536,350.00. Following the completion of the sale, the director owned 34,905 shares in the company, valued at $3,744,259.35. The trade was a 12.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Joseph E. Gilliam sold 19,340 shares of Glaukos stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $90.00, for a total transaction of $1,740,600.00. Following the completion of the transaction, the chief operating officer directly owned 92,366 shares of the company’s stock, valued at $8,312,940. This trade represents a 17.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 24,655 shares of company stock valued at $2,310,025. Corporate insiders own 5.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Smartleaf Asset Management LLC increased its stake in Glaukos by 16.2% in the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock valued at $99,000 after buying an additional 136 shares during the period. UMB Bank n.a. lifted its holdings in shares of Glaukos by 102.6% during the 3rd quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 158 shares during the last quarter. Park Place Capital Corp grew its stake in shares of Glaukos by 68.4% in the 2nd quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock valued at $41,000 after buying an additional 162 shares in the last quarter. Harbor Capital Advisors Inc. grew its position in Glaukos by 0.4% in the second quarter. Harbor Capital Advisors Inc. now owns 39,305 shares of the medical instruments supplier’s stock worth $4,060,000 after acquiring an additional 173 shares in the last quarter. Finally, Focus Partners Wealth increased its stake in shares of Glaukos by 6.9% during the 3rd quarter. Focus Partners Wealth now owns 2,714 shares of the medical instruments supplier’s stock worth $202,000 after purchasing an additional 176 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.